Antipsychotics in Dementia

Uses

Risks & contraindications

Highlighted claims

• Antipsychotic use in patients with dementia is linked to sedation, accelerated cognitive decline, and increased mortality. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study
• Deprescribing antipsychotics is strongly recommended for dementia-related behavioural and psychological symptoms after at least 3 months without improvement or after symptom stabilisation. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study
• Ongoing antipsychotic therapy should be regularly evaluated for all dementia patients receiving it. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study
• The mortality risk from antipsychotics is especially relevant in individuals with Lewy body dementia. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study